These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
217 related items for PubMed ID: 1906351
21. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1. Li XK, Lijnen HR, Nelles L, Van Hoef B, Stassen JM, Collen D. Blood; 1992 Jan 15; 79(2):417-29. PubMed ID: 1730087 [Abstract] [Full Text] [Related]
24. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis. Van de Werf F, Jang IK, Collen D. J Cardiovasc Pharmacol; 1987 Jan 15; 9(1):91-3. PubMed ID: 2434801 [Abstract] [Full Text] [Related]
28. K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in man. Collen D, Nelles L, De Cock F, Lemmens G, Van Coetsem T, Demarsin E, Lijnen HR. Thromb Res; 1992 Feb 01; 65(3):421-38. PubMed ID: 1631805 [Abstract] [Full Text] [Related]
29. Comparison of dose regimens for the administration of recombinant pro-urokinase in a canine thrombosis model. Burke SE, Lubbers NL, Nelson RA, Henkin J. Thromb Haemost; 1997 May 01; 77(5):1025-30. PubMed ID: 9184422 [Abstract] [Full Text] [Related]
30. Comparative thrombolytic properties of single-chain forms of urokinase-type plasminogen activator. Stump DC, Stassen JM, Demarsin E, Collen D. Blood; 1987 Feb 01; 69(2):592-6. PubMed ID: 3099862 [Abstract] [Full Text] [Related]
31. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis. Ziskind AA, Gold HK, Yasuda T, Kanke M, Guerrero JL, Fallon JT, Saito T, Collen D. Circulation; 1989 Feb 01; 79(2):393-9. PubMed ID: 2492455 [Abstract] [Full Text] [Related]
32. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group. Lancet; 1989 Apr 22; 1(8643):863-8. PubMed ID: 2564949 [Abstract] [Full Text] [Related]
33. Synergy of in vitro thrombolytic action of combinations of recombinant staphylokinase and single-chain urokinase-type plasminogen activator. Aisina RB, Moukhametova LI, Varfolomeyev SD. Biochemistry (Mosc); 2003 Nov 22; 68(11):1252-60. PubMed ID: 14640969 [Abstract] [Full Text] [Related]
34. New developments in thrombolytic therapy. Collen D, Gold HK. Adv Exp Med Biol; 1990 Nov 22; 281():333-54. PubMed ID: 2129372 [Abstract] [Full Text] [Related]
35. A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma. Declerck PJ, Lijnen HR, Verstreken M, Moreau H, Collen D. Blood; 1990 May 01; 75(9):1794-800. PubMed ID: 1691934 [Abstract] [Full Text] [Related]
36. Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction. Diefenbach C, Erbel R, Pop T, Mathey D, Schofer J, Hamm C, Ostermann H, Schmitz-Hübner U, Bleifeld W, Meyer J. Am J Cardiol; 1988 May 01; 61(13):966-70. PubMed ID: 2452563 [Abstract] [Full Text] [Related]
37. Thrombolytic therapy. Collen D, Stump DC, Gold HK. Annu Rev Med; 1988 May 01; 39():405-23. PubMed ID: 3130773 [Abstract] [Full Text] [Related]